<DOC>
	<DOCNO>NCT00236860</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety topiramate add-on therapy epilepsy patient difficult treat , partial-onset seizure take one two standard anti-epileptic drug .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate add-on Therapy Treatment Epilepsy Patients With Difficult Treat , Partial-onset Seizures</brief_title>
	<detailed_description>Epilepsy characterize seizure , abnormal electrical discharge brain temporarily disrupt normal brain function . Seizures classified `` generalize , '' originate side brain simultaneously , `` partial-onset , '' start one area brain . Antiepilepsy medication , topiramate , select base seizure type . This double-blind , placebo-controlled study adult patient difficult treat partial epilepsy include baseline phase treatment phase . During baseline phase ( 8 week duration ) , patient receive one two standard antiepileptic drug ( AEDs ) , phenytoin , carbamazepine , phenobarbital , primidone , valproic acid . Patients continue seizure treatment standard AEDs proceed double-blind treatment phase . Patients receive topiramate placebo dosage 100-milligrams ( mg ) daily , increase gradually 5 week 4 tablet twice daily ( 800 mg/day ) maximum tolerate dose , maintain dose 8 week ( 13 week total duration double-blind phase ) , continue standard AED regimen . Assessments effectiveness include percent reduction average monthly seizure rate , percent patient respond treatment ( equal great 50 % reduction seizure rate ) , patient 's investigator 's global assessment medication end study . Safety assessment include incidence adverse event throughout study , clinical laboratory test ( hematology , serum chemistry , urinalysis ) , neurologic examination , vital sign measurement ( blood pressure , pulse , temperature ) weekly treatment phase . The study hypothesis topiramate , take add-on therapy treatment AEDs , significantly reduce seizure frequency , compare placebo , patient refractory partial epilepsy : , patient continue seizures despite treatment first-line AEDs . In addition , hypothesize topiramate well tolerate . Topiramate , 100 mg oral tablet , match placebo tablet . Dosage begin 100 mg daily increase gradually 5 week 4 tablet twice daily ( 800 mg/day , maximum ) maximum tolerate dose additional 8 week . Doses may increase decreased investigator 's discretion .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>History simple complex partial epilepsy document witnessed electroencephalogram ( EEG ) precede 5 year pattern consistent diagnosis partial epilepsy 8week baseline phase , patient must least 8 partial seizure maintain therapeutic level antiepileptic drug ( AEDs ) one seizurefree interval 3 week seizurefree interval long 3 week good physical health . Patients solely generalized seizure lack documentation partial epilepsy patient generalize tonicclonic seizure generalize epilepsy absence EEG consistent partial epilepsy generalize seizure , define EEG wave pattern seizures lack abnormal pulsation pattern EEG females capable child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>partial seizure disorder</keyword>
	<keyword>brain disease</keyword>
	<keyword>topiramate</keyword>
	<keyword>epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>epileptic seizure</keyword>
</DOC>